Soleno Therapeutics (SLNO) Accounts Payables (2016 - 2019)
Historic Accounts Payables for Soleno Therapeutics (SLNO) over the last 7 years, with Q3 2019 value amounting to $1.7 million.
- Soleno Therapeutics' Accounts Payables rose 3935.74% to $1.7 million in Q3 2019 from the same period last year, while for Sep 2019 it was $1.7 million, marking a year-over-year increase of 3935.74%. This contributed to the annual value of $934000.0 for FY2018, which is 4755.13% up from last year.
- Latest data reveals that Soleno Therapeutics reported Accounts Payables of $1.7 million as of Q3 2019, which was up 3935.74% from $1.7 million recorded in Q2 2019.
- In the past 5 years, Soleno Therapeutics' Accounts Payables ranged from a high of $1.7 million in Q2 2019 and a low of $410512.0 during Q4 2016
- In the last 5 years, Soleno Therapeutics' Accounts Payables had a median value of $957000.0 in 2016 and averaged $1.0 million.
- Over the last 5 years, Soleno Therapeutics' Accounts Payables had its largest YoY gain of 10322.06% in 2016, and its largest YoY loss of 4093.83% in 2016.
- Soleno Therapeutics' Accounts Payables (Quarter) stood at $695056.0 in 2015, then crashed by 40.94% to $410512.0 in 2016, then soared by 54.2% to $633000.0 in 2017, then skyrocketed by 47.55% to $934000.0 in 2018, then surged by 85.76% to $1.7 million in 2019.
- Its last three reported values are $1.7 million in Q3 2019, $1.7 million for Q2 2019, and $1.3 million during Q1 2019.